Pharmaceuticals 2010, 3(5), 1348-1359; doi:10.3390/ph3051348
Review

Health Economics of Antibiotics

Received: 29 March 2010; in revised form: 19 April 2010 / Accepted: 23 April 2010 / Published: 29 April 2010
(This article belongs to the Special Issue Antibiotics)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Antibiotics have made a significant contribution to improving patient health, but policy makers and health care payers are concerned about the costs of antibiotics in addition to their effectiveness. This paper aims to assess the value of antibiotics by examining incremental cost-utility ratios of antibiotics. Evidence was derived from cost-utility analyses of antibiotics included in the Tufts-New England Center Cost-Effectiveness Analysis Registry through September 2009. The analysis included 85 incremental cost-utility ratios from 23 cost-utility analyses. The findings showed that 38.8% of incremental cost-utility ratios related to dominant antibiotics (i.e., more effective and less costly than the comparator); 45.9% referred to antibiotics that improved effectiveness, but also increased costs; and 15.3% related to dominated antibiotics (i.e., less effective and more costly than the comparator). The median ratio was 748 € per quality-adjusted life year. Using threshold values of 20,000 € per quality-adjusted life year and 50,000 € per quality-adjusted life year, the probability that an antibiotic provides value for money was 64% and 67%, respectively. The current evidence base suggests that the majority of antibiotics provide value for money and that antibiotics can aid decision makers to attain further population health improvements, whilst containing pharmaceutical expenditures.
Keywords: health economics; antibiotics; cost-utility analysis; incremental cost-utility ratio
PDF Full-text Download PDF Full-Text [200 KB, uploaded 29 April 2010 10:02 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Simoens, S. Health Economics of Antibiotics. Pharmaceuticals 2010, 3, 1348-1359.

AMA Style

Simoens S. Health Economics of Antibiotics. Pharmaceuticals. 2010; 3(5):1348-1359.

Chicago/Turabian Style

Simoens, Steven. 2010. "Health Economics of Antibiotics." Pharmaceuticals 3, no. 5: 1348-1359.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert